Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in Advanced Rare Tumours
NCT02879162Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Dec 2016
- Primary completion
- Jun 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in Neoplasm, salivary gland carcinoma (SGC), carcinoma of unknown primary (CUP), mucosal melanoma (MM), acral lentiginous melanoma (ALM), sponsored by Canadian Cancer Trials Group. Started Dec 2016; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
Neoplasmsalivary gland carcinoma (SGC)carcinoma of unknown primary (CUP)mucosal melanoma (MM)acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT02879162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02879162.